Islet cells in human type 1 diabetes: from recent advances to novel therapies - a symposium-based roadmap for future research

James Cantley (Lead / Corresponding author), Decio Laks Eizirik, Esther Latres, Colin M. Dayan

    Research output: Contribution to journalReview articlepeer-review

    3 Citations (Scopus)
    66 Downloads (Pure)

    Abstract

    There is a growing understanding that the early phases of type 1 diabetes (T1D) are characterised by a deleterious dialogue between the pancreatic beta cells and the immune system. This, combined with the urgent need to better translate this growing knowledge into novel therapies, provided the background for the JDRF-DiabetesUK-INNODIA-nPOD symposium entitled 'Islet cells in human T1D: from recent advances to novel therapies', which took place in Stockholm, Sweden, in September 2022. We provide in this article an overview of the main themes addressed in the symposium, pointing to both promising conclusions and key unmet needs that remain to be addressed in order to achieve better approaches to prevent or reverse T1D.

    Original languageEnglish
    Article numbere230082
    Number of pages20
    JournalJournal of Endocrinology
    Volume259
    Issue number1
    Early online date26 Jul 2023
    DOIs
    Publication statusPublished - 31 Aug 2023

    Keywords

    • islet
    • pancreas
    • insulin secretion
    • autoimmune
    • diabetes

    ASJC Scopus subject areas

    • Endocrinology
    • Endocrinology, Diabetes and Metabolism

    Fingerprint

    Dive into the research topics of 'Islet cells in human type 1 diabetes: from recent advances to novel therapies - a symposium-based roadmap for future research'. Together they form a unique fingerprint.

    Cite this